The sepsis therapeutics market is set to expand over the next several years, a Transparency Market Research report found, according to medGadget.
Here are four highlights:
1. North American leads the market due to a high incidence of sepsis and more public awareness about sepsis complications. Sepsis infected 1.16 million U.S. residents annually last year.
2. A growing incidence rate and increased sepsis research is fueling European growth.
3. Factors spurring expansion include a higher prevalence of hospital-acquired infections and an increasing surgical demand.
4. Companies operating in the market include:
● Adrenomed
● Altor BioScience Corp.
● Boehringer Ingelheim
● Bristol-Myers Squibb Co.
● InflaRx
● Inotrem